LINICAL ACCELOVANCE AMERICA, INC.
STUART, FLORIDA

LINICAL ACCELOVANCE AMERICA, INC., originally incorporated in Florida on April 04, 2006, with a mailing address at 789 SW FEDERAL HIGHWAY, SUITE 212, STUART, FL, has positioned itself as a distinguished leader in the clinical research industry. The company was founded by Mr. Trevisan, an accomplished entrepreneur with experience in establishing successful Contract Research Organization (CRO) companies that have demonstrated substantial growth and have been acquired by public entities. The corporate mission of Accelovance is to provide innovative treatments through clinical development by bringing together outstanding expertise in clinical research. This mission is advanced through the leadership of key figures, including Jeffrey T. Rudolph with extensive CRO and pharmaceutical experience, Dr. Dave leading the Medical Affairs & Drug Safety group with decades of clinical research experience across various medical fields, Dr. Oliver as Chief Science Officer with strategic scientific insight from his tenure in both academia and industry roles, and Dr. Wendy (Wen-Ying) Wang who oversees operations in China focusing on regulatory consultancy and global clinical trials. Accelovance has consistently been recognized for its excellence, evidenced by receiving a ‘World Leader’ designation twice consecutively and a 'Highly Recommended' distinction in 2013 by TopTenRev. The company's capability to manage budgets, timelines effectively, and increase patient enrollment rates underscores its business acumen and commitment to meeting the clinical needs of their clients. Located primarily in Stuart, Florida, Accelovance continues to excel as a full-service contract research organization (CRO) with its broad expertise spanning across various clinical trial phases and therapeutic areas. Its strategic operations are supported by an experienced professional team adept at navigating the complex landscape of pharmaceutical services from inception to large-scale revenue generation.